Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.41 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.36 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.36 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20639926 | 0.89 | GAA (0.36) | PTGS2DNMT1GAAMAP3K5MAPT | |
| SCHEMBL28511063 | 0.84 | MCL1 (0.47) | PTGS2MCL1BCL2BCL2L2FPR2 | |
| SCHEMBL16138185 | 0.82 | MDM2 (0.36) | PTGS2GAAMAPTPOLBALDH1A1 | |
| SCHEMBL16144684 | 0.80 | HSD17B10 (0.54) | GAAMAPTMCL1MEN1KMT2A | |
| SCHEMBL17512291 | 0.80 | PTGS2 (0.46) | PTGS2FPR2ALDH1A1 | |
| SCHEMBL16137841 | 0.79 | GCK (0.40) | PTGS2 | |
| SCHEMBL16144668 | 0.77 | ALDH1A1 (0.40) | PTGS2GAAMAPTMCL1MEN1 | |
| SCHEMBL19066704 | 0.76 | PTGS2 (0.34) | PTGS2GAAMAPTPOLBALDH1A1 | |
| SCHEMBL21459642 | 0.76 | SMAD3 (0.40) | MAPTMCL1KDM4EBCL2BCL2L2 | |
| SCHEMBL17503983 | 0.74 | SLC1A1 (0.47) | PTGS2GAAMAPTMCL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-9822102-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20160368903-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | US | disclosed |
| US-9434690-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-06 | — | — | US | disclosed |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | OGFOD1, VASP, PNPO | PTGS2 334/4885DNMT1 3014/4885GAA 1603/4885 |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | OGFOD1, PNPO, VASP | PTGS2 338/4885DNMT1 2624/4885GAA 1468/4885 |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | OGFOD1, PNPO, VASP | PTGS2 338/4885DNMT1 2624/4885GAA 1468/4885 |
| US-20160368903-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | OGFOD1, PNPO, VASP | PTGS2 338/4885DNMT1 2624/4885GAA 1468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.